GlobalFoundries announced its Q2 2026 financial results with revenue of $1.786 billion, exceeding the high end of its guidance. The company reported a gross margin of 28.3% and a net income of $167 million, driven by strong demand in AI data center and optical networking technologies. Key business moves include a $300 million U.S. Department of Commerce award to advance silicon photonics, acquisitions to enhance power delivery and RISC-V IP solutions, and launching Quantum Technology Solutions. The company also paid its first-ever quarterly dividend and expects continued growth in Q3 2026 with revenue guidance around $1.885 billion.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
